{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:13:51Z","timestamp":1783487631403,"version":"3.55.0"},"reference-count":66,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: The permanence of contemporary coronary stents is associated with chronic complications, particularly in-stent restenosis and stent thrombosis. Poly-L-lactic-acid-based bioresorbable stents were withdrawn given late stent thrombosis risk. Magnesium-based bioresorbable stents (MgBRS) have emerged as promising alternatives. This study documents the safety and efficacy profile of MgBRS generations. Methods: A systematic review was performed using EMBASE, MEDLINE and Web of Science (2007 to August 2025). Studies include individuals requiring percutaneous coronary intervention for coronary artery disease with MgBRS. Primary outcomes were cardiac death, definite\/probable scaffold thrombosis and target vessel failure (TVF), organised into \u226412, \u226424, \u226436 and \u226460 months. The secondary outcome was late lumen loss (LLL). Results: Four MgBRS generations were identified: AMS-1, DREAMS 1G, Magmaris and Freesolve; and 25 studies were included. Cardiac death and stent thrombosis rates were under 1.0% up to 24 months for all, and 0% with Freesolve at 36 months. AMS-1 had the highest TVF rate at 44.4% at 12 months, improving to 3.6% at 36 months in Freesolve. Only Magmaris had 60-month data, showing 3.4% cardiac death, 2.7% stent thrombosis and 16.4% TVF rates. The data suggest improvement in 12-month LLL: DREAMS 1G (0.4 \u00b1 0.3 mm), Magmaris (0.5 \u00b1 1.1 mm) and Freesolve (0.2 \u00b1 0.4 mm). Conclusions: Each successive generation demonstrated improvement in all studied outcomes since the underperformance of AMS-1. The favourable performance of Freesolve is comparable to contemporary drug-eluting stents. Results of randomised head-to-head trials are anticipated.<\/jats:p>","DOI":"10.3390\/jcm15135003","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T08:45:20Z","timestamp":1782722720000},"page":"5003","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Comparison of Performance of the Different Generations of Magnesium-Based Bioresorbable Coronary Stents"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5813-6395","authenticated-orcid":false,"given":"Jeremy","family":"Ang","sequence":"first","affiliation":[{"name":"Cardiac Services, Townsville University Hospital, Townsville, QLD 4814, Australia"},{"name":"Tasmanian School of Medicine, University of Tasmania, Hobart, TAS 7000, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7623-6402","authenticated-orcid":false,"given":"Liam Marsden","family":"Back","sequence":"additional","affiliation":[{"name":"Eastern Heart Clinic, Prince of Wales Hospital, Randwick, NSW 2031, Australia"},{"name":"MRC Clinical Trials Unit, University College London, London WC1V 6LJ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(78)90500-7","article-title":"Transluminal dilatation of coronary-artery stenosis","volume":"1","author":"Gruntzig","year":"1978","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1056\/NEJM198703193161201","article-title":"Intravascular Stents to Prevent Occlusion and Re-Stenosis after Transluminal Angioplasty","volume":"316","author":"Sigwart","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJM199408253310801","article-title":"A Comparison of Balloon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease","volume":"331","author":"Serruys","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJM199408253310802","article-title":"A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease","volume":"331","author":"Fischman","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.jcin.2015.05.026","article-title":"Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy","volume":"8","author":"Kereiakes","year":"2015","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1161\/01.CIR.94.6.1247","article-title":"Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study","volume":"94","author":"Hoffmann","year":"1996","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1161\/01.CIR.0000069331.67148.2F","article-title":"New Frontiers in Cardiology","volume":"107","author":"Sousa","year":"2003","journal-title":"Circulation"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.3390\/jpm12091378","article-title":"Ultrathin Struts Drug-Eluting Stents: A State-of-the-Art Review","volume":"12","author":"Leone","year":"2022","journal-title":"J. Pers. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0140-6736(12)60324-9","article-title":"Stent thrombosis with drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-analysis","volume":"379","author":"Palmerini","year":"2012","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1161\/ATVBAHA.107.144220","article-title":"Vascular responses to drug eluting stents: Importance of delayed healing","volume":"27","author":"Finn","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1161\/CIRCULATIONAHA.115.019071","article-title":"Mechanisms of Very Late Drug-Eluting Stent Thrombosis Assessed by Optical Coherence Tomography","volume":"133","author":"Taniwaki","year":"2016","journal-title":"Circulation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.repc.2020.12.004","article-title":"The third generation of drug-eluting stents: Reassuring data while we wait for the next one","volume":"40","year":"2021","journal-title":"Rev. Port. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/CM9.0000000000002450","article-title":"Five-year outcomes of biodegradable versus second-generation durable polymer drug-eluting stents used in complex percutaneous coronary intervention","volume":"136","author":"Xu","year":"2023","journal-title":"Chin. Med. J."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Lee, S.J., Choi, D.W., Suh, Y., Hong, S.J., Ahn, C.M., Kim, J.S., Kim, B.K., Ko, Y.G., Choi, D., and Park, E.C. (2022). Long-Term Clinical Outcomes Between Biodegradable and Durable Polymer Drug-Eluting Stents: A Nationwide Cohort Study. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.873114"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1161\/CIRCULATIONAHA.106.683995","article-title":"Late Coronary Stent Thrombosis","volume":"116","author":"Windecker","year":"2007","journal-title":"Circulation"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(04)17275-9","article-title":"Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy","volume":"364","author":"McFadden","year":"2004","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.4244\/EIJY14M07_11","article-title":"Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: Early and midterm outcomes from the European multicentre GHOST-EU registry","volume":"10","author":"Capodanno","year":"2015","journal-title":"EuroIntervention"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"V181","DOI":"10.4244\/EIJV11SVA43","article-title":"What about the risk of thrombosis with bioresorbable scaffolds?","volume":"11","author":"Capodanno","year":"2015","journal-title":"EuroIntervention"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"24492","DOI":"10.3390\/ijms141224492","article-title":"Bioresorbable drug-eluting magnesium-alloy scaffold for treatment of coronary artery disease","volume":"14","author":"Campos","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/S0140-6736(07)60853-8","article-title":"Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: A prospective, non-randomised multicentre trial","volume":"369","author":"Erbel","year":"2007","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0140-6736(12)61765-6","article-title":"Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial","volume":"381","author":"Haude","year":"2013","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.4244\/EIJ-D-15-00371","article-title":"Safety and performance of the DRug-Eluting Absorbable Metal Scaffold (DREAMS) in patients with de novo coronary lesions: 3-year results of the prospective, multicentre, first-in-man BIOSOLVE-I trial","volume":"12","author":"Haude","year":"2016","journal-title":"EuroIntervention"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)00447-X","article-title":"Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial","volume":"387","author":"Haude","year":"2016","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e1375","DOI":"10.4244\/EIJ-D-18-01000","article-title":"Safety and performance of the second-generation drug-eluting absorbable metal scaffold (DREAMS 2G) in patients with de novo coronary lesions: Three-year clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial","volume":"15","author":"Haude","year":"2020","journal-title":"EuroIntervention"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.carrev.2021.07.017","article-title":"Sustained Safety and Performance of a Second-Generation Sirolimus-Eluting Absorbable Metal Scaffold: Long-Term Data of the BIOSOLVE-II First-in-Man Trial at 5 Years","volume":"38","author":"Haude","year":"2022","journal-title":"Cardiovasc. Revasc. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1093\/eurheartj\/ehw196","article-title":"Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial","volume":"37","author":"Haude","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"432","DOI":"10.4244\/EIJ-D-17-00254","article-title":"Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: Pooled outcomes of BIOSOLVE-II and BIOSOLVE-III","volume":"13","author":"Haude","year":"2017","journal-title":"EuroIntervention"},{"key":"ref_30","first-page":"E502","article-title":"Safety and clinical performance of a drug eluting absorbable metal scaffold in the treatment of subjects with de novo lesions in native coronary arteries: Pooled 12-month outcomes of BIOSOLVE-II and BIOSOLVE-III","volume":"92","author":"Haude","year":"2018","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.carrev.2022.05.028","article-title":"Magmaris Resorbable Magnesium Scaffold Versus Conventional Drug-Eluting Stent in ST-Segment Elevation Myocardial Infarction: 1-Year Results of a Propensity-Score-Matching Comparison","volume":"43","author":"Xaplanteris","year":"2022","journal-title":"Cardiovasc. Revasc. Med."},{"key":"ref_32","first-page":"E287","article-title":"Early outcome of magnesium bioresorbable scaffold implantation in acute coronary syndrome-the initial report from the Magmaris-ACS registry","volume":"93","author":"Wlodarczak","year":"2019","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_33","first-page":"67","article-title":"Magnesium bioresorbable scaffold (Magmaris) versus polymer biodegradable ultrathin drug-eluting stent (Ultimaster) in acute coronary syndrome. Mid-term outcomes (2 years)","volume":"20","author":"Rola","year":"2024","journal-title":"Adv. Interv. Cardiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1161\/CIRCULATIONAHA.119.043467","article-title":"Magnesium-Based Resorbable Scaffold Versus Permanent Metallic Sirolimus-Eluting Stent in Patients With ST-Segment Elevation Myocardial Infarction: The MAGSTEMI Randomized Clinical Trial","volume":"140","author":"Alfonso","year":"2019","journal-title":"Circulation"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.4244\/EIJ-D-21-00651","article-title":"Magnesium-based resorbable scaffold vs. permanent metallic sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction: 3-year results of the MAGSTEMI randomised controlled trial","volume":"18","author":"Brugaletta","year":"2022","journal-title":"EuroIntervention"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"ehz746.0580","DOI":"10.1093\/eurheartj\/ehz746.0580","article-title":"P5637A novel bioresorbable magnesium-based stent: Initial clinical results and 6-months follow-up by coronary computed tomography angiography scan","volume":"40","author":"Ghafari","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S0735-1097(20)32131-8","article-title":"Differential Efficacy of a New Magnesium-Based Bioresorbable Stent in Chronic and Acute Coronary Syndromes","volume":"75","author":"Carlier","year":"2020","journal-title":"JACC"},{"key":"ref_38","first-page":"E1","article-title":"BIOSOLVE-IV-registry: Safety and performance of the Magmaris scaffold: 12-month outcomes of the first cohort of 1,075 patients","volume":"98","author":"Verheye","year":"2021","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_39","first-page":"232","article-title":"One- and two-year clinical outcomes of treatment with resorbable magnesium scaffolds for coronary artery disease: The prospective, international, multicentre BIOSOLVE-IV registry","volume":"19","author":"Wlodarczak","year":"2023","journal-title":"EuroIntervention"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.repc.2019.09.018","article-title":"12-month clinical outcomes after Magmaris percutaneous coronary intervention in a real-world cohort of patients: Results from the CardioHULA registry","volume":"39","year":"2020","journal-title":"Rev. Port. Cardiol."},{"key":"ref_41","first-page":"C49","article-title":"Twelve-month outcome of resorbable magnesium scaffold in real-world complex percutaneous coronary interventions: The Magic Registry. 52nd ANMCO Congress Abstracts e-Posters","volume":"23","author":"Franze","year":"2021","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_42","first-page":"E69","article-title":"Long-term clinical, angiographic, and optical coherence tomography findings of Mg-based bioresorbable scaffold in patients with acute coronary syndrome","volume":"98","author":"Gheorghe","year":"2021","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_43","first-page":"1075","article-title":"Bioresorbable magnesium scaffold in the treatment of simple coronary bifurcation lesions: The BIFSORB pilot II study","volume":"99","author":"Barkholt","year":"2022","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s10557-021-07258-z","article-title":"Comparison of a Bioresorbable, Magnesium-Based Sirolimus-Eluting Stent with a Permanent, Everolimus-Eluting Metallic Stent for Treating Patients with Acute Coronary Syndrome: The PRAGUE-22 Study","volume":"36","author":"Neuberg","year":"2022","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.carrev.2021.12.003","article-title":"Optical Coherence Tomography- Versus Angiography-Guided Magnesium Bioresorbable Scaffold Implantation in NSTEMI Patients","volume":"40","author":"Fallesen","year":"2022","journal-title":"Cardiovasc. Revasc. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.carrev.2022.01.020","article-title":"Sustained Safety and Efficacy of Magnesium Reabsorbable Scaffold: 2-Year Follow-Up Analysis From First Magmaris Multicenter Italian Registry","volume":"41","author":"Galli","year":"2022","journal-title":"Cardiovasc. Revasc. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.3390\/jcm11133726","article-title":"Long-Term Performance of the Magmaris Drug-Eluting Bioresorbable Metallic Scaffold in All-Comers Patients\u2019 Population","volume":"11","author":"Aboushokka","year":"2022","journal-title":"J. Clin. Med."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Bossard, M., Madanchi, M., Avdijaj, D., Attinger-Toller, A., Cioffi, G.M., Seiler, T., Tersalvi, G., Kobza, R., Sch\u00fcpfer, G., and Cuculi, F. (2022). Long-Term Outcomes After Implantation of Magnesium-Based Bioresorbable Scaffolds-Insights From an All-Comer Registry. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.856930"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Truong, B.Q., Tran, H., Nguyen, V.X., Nguyen, C.D., Nguyen, K.D., and Vu, V.H. (2023). Mid-term safe and effective profile of the Magmaris scaffold in percutaneous coronary intervention: A prospective, single-center study. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1194933"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"D22","DOI":"10.1093\/eurheartjsupp\/suad111.053","article-title":"C54 Acute and Long Term Performance of Magmaris Bioresorbable Scaffold Implantation in Spontaneous Coronary Artery Dissection (SCAD): The Experience of the Coordinator Center of the International Multicenter Registry Disco","volume":"25","author":"Giacobbe","year":"2023","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2023.04.029","article-title":"Long-term outcomes of patients treated with sirolimus-eluting resorbable magnesium scaffolds: Insights from the SHERPA-MAGIC study","volume":"383","author":"Pompei","year":"2023","journal-title":"Int. J. Cardiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"B55","DOI":"10.1016\/j.jacc.2023.09.147","article-title":"TCT-141 Preliminary Results of the Resorbable Magnesium Scaffold (Magmaris) in Long and Multivessel Lesions: Data from the IT-Masters Registry","volume":"82","author":"Galli","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.4244\/EIJ-D-23-00326","article-title":"A new resorbable magnesium scaffold for de novo coronary lesions (DREAMS 3): One-year results of the BIOMAG-I first-in-human study","volume":"19","author":"Haude","year":"2023","journal-title":"EuroIntervention"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"971","DOI":"10.4244\/EIJ-D-25-00396","article-title":"Clinical outcomes of the third-generation resorbable magnesium scaffold for coronary artery lesions: Three-year results of the BIOMAG-I study","volume":"21","author":"Haude","year":"2025","journal-title":"EuroIntervention"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s40001-024-01949-7","article-title":"Comparative effectiveness of ultrathin vs. standard strut drug-eluting stents: Insights from a large-scale meta-analysis with extended follow-up","volume":"29","author":"Hassan","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"ref_56","first-page":"575","article-title":"The relationship between coronary stent strut thickness and the incidences of clinical outcomes after drug-eluting stent implantation: A systematic review and meta-regression analysis","volume":"99","author":"Saito","year":"2022","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1016\/j.jacc.2017.09.014","article-title":"Mechanisms of Very Late Bioresorbable Scaffold Thrombosis","volume":"70","author":"Yamaji","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e1040","DOI":"10.4244\/EIJ-D-17-00708","article-title":"Preclinical evaluation of degradation kinetics and elemental mapping of first- and second-generation bioresorbable magnesium scaffolds","volume":"14","author":"Joner","year":"2018","journal-title":"EuroIntervention"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"26691","DOI":"10.1038\/s41598-024-77266-0","article-title":"A novel stent flow chamber system demonstrates reduced thrombogenicity of bioresorbable magnesium scaffolds","volume":"14","author":"Ludwig","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0002-9149(00)01085-7","article-title":"Long-term outcomes of minor dissection at the edge of stents detected with intravascular ultrasound","volume":"86","author":"Hong","year":"2000","journal-title":"Am. J. Cardiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jacc.2015.08.853","article-title":"Very Late Scaffold Thrombosis: Intracoronary Imaging and Histopathological and Spectroscopic Findings","volume":"66","author":"Brugaletta","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.jacc.2015.11.062","article-title":"Mechanisms of Late and Very Late Bioresorbable Vascular Scaffold Thrombosis","volume":"67","author":"Arroyo","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.atherosclerosis.2010.10.046","article-title":"The relationship between late lumen loss and restenosis among various drug-eluting stents: A systematic review and meta-regression analysis of randomized clinical trials","volume":"214","author":"Brener","year":"2011","journal-title":"Atherosclerosis"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.amjcard.2003.10.049","article-title":"Impact of strut thickness on late luminal loss after coronary artery stent placement","volume":"93","author":"Rittersma","year":"2004","journal-title":"Am. J. Cardiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/CIRCINTERVENTIONS.111.964270","article-title":"Late positive remodeling and late lumen gain contribute to vascular restoration by a non-drug eluting bioresorbable scaffold: A four-year intravascular ultrasound study in normal porcine coronary arteries","volume":"5","author":"Strandberg","year":"2012","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_66","unstructured":"Biotronik, A.G. (2026, January 15). Safety and Clinical Performance of the Drug Eluting Resorbable Coronary Magnesium Scaffold System (Freesolve\u00ae) in the Treatment of Subjects with De Novo Lesions in Native Coronary Arteries: BIOMAG-II: A Randomized Controlled Trial, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05540223."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5003\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:23:22Z","timestamp":1783484602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":66,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15135003"],"URL":"https:\/\/doi.org\/10.3390\/jcm15135003","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]}}}